PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
Retrieved on:
Monday, December 19, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Lymphatic system, PAM, Annual report, Patient, U.S. FDA, Journal of the Neurological Sciences, Monash University, Benzodiazepine, University of Melbourne, Disorder, Liver, Immune system, Journal, Environment, Depression, Evaluation, Angewandte Chemie, Kathryn Bullock, PRTC, Drug development, Pharmacy, Allopregnanolone, FDA, Safety, Clinical trial, PPD, LSE, CDER, GABA, Multimedia, Fat, Food, PureTech Health, Pharmacology, Parkinson's disease, Monash Institute of Medical Research, Therapy, Journal of Controlled Release, Platform supply vessel, GABAA, Research, Control, Pharmaceutical industry, Vaccine, CBD, Glyph, List of Nature Research journals
View the full release here: https://www.businesswire.com/news/home/20221219005209/en/
Key Points:
- View the full release here: https://www.businesswire.com/news/home/20221219005209/en/
PureTech announced topline results for LYT-300 (oral allopregnanolone), a therapeutic candidate in development for neurological and neuropsychological conditions. - The results show that oral administration of LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic benefit and results in exposure-dependent target engagement of GABAA receptors.
- The impact of LYT-300 on b-EEG and other markers of GABAA target engagement were also assessed.
- PureTech completed a Phase 1 clinical trial of LYT-300 in 2022, which demonstrated oral bioavailability, tolerability and GABAA receptor target engagement in healthy volunteers.